Targeting CXCR4/CXCL12 axis via [ 177 Lu]Lu-DOTAGA.(SA.FAPi) 2 with CXCR4 antagonist in triple-negative breast cancer.

Guangfa BaoZiqiang WangLuoxia LiuBuchuan ZhangShuang SongDongdong WangSiyuan ChengEu-Song MoonFrank RoeschJun ZhaoBo YuXiaohua Zhu

Published in: European journal of nuclear medicine and molecular imaging (2024)

and AMD3100 is a feasible treatment against TNBC with minimal toxicity in main organs.

Keyphrases